Could carbon monoxide be a medicine? new trial for sickle cell
NCT ID NCT06144749
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study tests a new liquid drug called HBI-002, which contains carbon monoxide, in 9 people with sickle cell disease aged 14 to 55. Participants take the drug daily for 14 days to see if it is safe and helps with symptoms. The goal is to find a better way to manage this painful blood disorder.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA, SICKLE CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cevaxin - The Panama Clinic
Panama City, Panama
-
Hospital Pacífica Salud
Panama City, Panama
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a computer program tame sickle cell pain crises?
- New App-Based program aims to help teens with sickle cell disease stay out of the ER
- Can telemedicine help kids with sickle cell disease get better care?
- Sickle cell transplant study halted after just one patient
- New transplant approach offers hope for sickle cell patients without a perfect donor match
- Sickle cell hope: drug combo raises hemoglobin in early trial